Single Gene Test
OncoCEPT Solid
(CEPT: Comprehensive Evaluation for Personalized Treatment)
Cancer is disease of the genome. Changes in genome or mutations lead to uncontrolled growth of cells and hence into tumors. While cancers are characterized by numerous genomic aberrations, some of these somatic mutations, known as
driver mutations, induce growth and impaired differentiation leading to cancer development. Various consortia such as The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (CGC) and such have sorted and identified driver
mutations in various different cancers, based on studies of thousands of tumor tissues. Various targeted therapies are developed against the specific mutations that drive the cancer tumor.
OncocEPT Solid identifies these driver mutations and helps in identifying targeted therapies, prognosis and clinical trials applicable to the patient.
Prominent technical features of OncoCEPT Solid:
- Enables the detection of variants in 52 key solid tumor genes. These genes are well characterized in the published literature and associated with oncology drugs that are FDA approved, part of National Comprehensive Cancer Network (NCCN) guidelines, or in clinical trials.
- The assay allows concurrent analysis of DNA and RNA.
- Simultaneously detect multiple types of variants, including hotspots, single nucleotide variants (SNVs), indels, CNVs, and gene fusions, in a single workflow.
- Uses formalin-fixed, paraffin embedded (FFPE) tissues, fine-needle aspirates, fresh tissues as starting sample.
TAT: 12 Working Days
OncoCEPT Solid Comprehensive:
(CEPT: Comprehensive Evaluation for Personalized Treatment)
Tumorigenesis in humans is a multistep process and that these steps reflect genetic alterations that drive the progressive transformation of normal human cells into highly malignant derivatives. Cancer treatment decisions are increasingly made on the basis of genomic information contained in the genes. OncoCEPT Solid Comprehensive test detects various multiple relevant biomarkers in a single next-generation sequencing (NGS) test by focusing on precision oncology.
OncocEPT Solid identifies these driver mutations and helps in identifying targeted therapies, prognosis and clinical trials applicable to the patient.
Prominent technical features of OncoCEPT Solid Comprehensive are:
- Enables the detection of variants in 161 key solid tumor genes. These genes are well characterized in the published literature and associated with oncology drugs that are FDA approved, part of NCCN (National Comprehensive Cancer Network) guidelines, or in clinical trials.
- They allow detection of single nucleotide variants (SNVs), copy number variations (CNVs), gene fusions, and Indels in a single workflow.
- Uses formalin fixed, paraffin embedded - FFPE tissues, fine needle aspirates, and fresh tissues as starting sample.
- This test is well characterized with molecular standards and controls necessary for validation.
TAT: 15 Working Days
OncoCEPT Liquid:
(CEPT: Comprehensive Evaluation for Personalized Treatment)
Cancer leads to formation of tumor. However, obtaining a tissue sample could be challenging. This leads to limiting amounts of tumor tissue being collected which is expected to be used for multiple and different types of investigations.
Often the investigations can’t be done due to the lack of sample. This test is noninvasive and cost-effective alternative to traditional biopsy samples, especially in lung and breast cancers.
Cancer also evolves Over time. Cancer may relapse after treatment of primary tumor. This relapse occurs due to change its genome. OncoCEPT Liquid can give snapshots of evolving cancer genome when the test is performed at period intervals. This information can help the oncologist pre-empt and modify treatment regimen.
Prominent technical features of OncoCEPT Liquid:
- Detection of somatic mutations in plasma, down to a level of o.1% in genes relevant to solid tumors.
- Analysis of single nucleotide variants, short indels, copy number variations, and fusions that are frequently mutated in research cancer samples.
- 150 hotspots in 11 genes focused on solid tumors, are analyzed.
- Sample type: whole blood.
TAT: 12 Working Days
Microsatellite instability (MSI):
In normal cells, the DNA mismatch repair (MMR) system recognizes and repairs genetic mismatches generated during DNA replication. A deficient MMR (dMMR) system results in the persistence of DNA mismatches in microsatellites that may then be incorporated into the genetic code as mutations which is sporadic in nature. Tumors that are deficient of DNA mismatch repair (MMR) system are designated as MSI-high and the once with intact MMR are called MSI-stable. Pembrolizumab is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H). These tumors are (1) Solid tumors that have progressed following prior treatment and who have no satisfactony alternative treatment options, or (2) colorectal cancer that has progressed following treatment with fluoropyrimidine, oxaliplatin, and irinotecan.
Prominent technical features of MSl test:
- Five microsatellite regions are analyzed.
TAT: 7 Working Days